Mircera (methoxy polyethylene glycol-epoetin beta)

Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.

Mircera is a long-acting erythropoietin stimulating agent (ESA) used for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients.1 It is the first Continuous Erythropoietin Receptor Activator (C.E.R.A.).2 It works like the human protein erythropoietin to help the body make more red blood cells and is used to reduce or avoid the need for red blood cell transfusion.1 The distinct molecular interaction of Mircera is believed to play an important role in providing targeted, stable and sustained control of anaemia.2

In Bangladesh Mircera is approved for the following indication.3

  • MIRCERA is indicated for the treatment of anaemia associated with chronic kidney disease (CKD).

  • Adult patients on dialysis and adult patients not on dialysis.

  • Pediatric patients from 3 months to less than 18 years of age on ESA maintenance treatment, either on dialysis or not on dialysis

For more disease and medicine related queries you may discuss with your physician.

In Bangladesh Mircera is available as

  • Pre-filled syringe containing 50 µg in 0.3 ml

  • Pre-filled syringe containing 75 µg in 0.3 ml

  • Pre-filled syringe containing 100 µg in 0.3 ml

is the authorized importer and distributor for Roche pharmaceutical medicines in Bangladesh. To meet strict quality and compliance, Radiant maintains temperature controlled supply chain.

To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.


  1. Global Website: Investors. Roche enters into exclusive license agreement with Galenica for the commercialisation of Mircera in the United States. (2015, May 28). [Internet; cited 2018, November 11]. Retrieved from

  2. Global Website: Investors. Mircera: first drug to correct anaemia in all chronic kidney disease patients with a simple twice-monthly dosing schedule. (2006, November 20). [Internet; cited 2018, November 11]. Retrieved from https://www.roche.com/investors/updates/inv-update-2006-11-20.htm

  3. Mircea-Product-Information-BD-Ro-0503821-February-2022


Mircera Product Information _ February-2022

Discover more


This website contains information which is targeted to the people of Bangladesh and could contain product details or information otherwise not accessible or valid in your country. Roche Bangladesh is not responsible for accessing such information that may not be in accordance with legal, regulatory, registration or use processes in your home country. Please note that, information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor. We are unable to answer questions on individual disease treatment/ management matters. These should be discussed with your physician. We cannot answer product-related questions through this website. Nor this site acts as promotional/ commercial tool for products. It is not permissible to take the contents of this site and use it for commercial purpose, without written consent of Roche Bangladesh.

ContactLocationslinkedinfacebooktwitterinstagramyoutubePharmacovigilanceAbout RochePharma solutionsRoche careersPersonalised healthcarePrivacy policyLegal statementCookie policy